OJMP  Vol.1 No.2 , April 2012
Correlates of Age at Initial Diagnosis of Chronic Lymphocytic Leukemia: Exercise, ASA & Emotional Distress
Abstract: Objective: No studies of either the cross-sectional or prospective association of behavioral life characteristics and the onset of Chronic Lymphocytic Leukemia (CLL) exist. Methods: Multiple interview or questionnaire measures of emotional distress and social support, as well as personality characteristics, exercise, sleep quality, aspirin or lipid-lowering medication use, smoking status and history, educational history and farming/pesticide exposure were tested as correlates of age at initial diagnosis of CLL (AAID-CLL) in 183 patients recruited from the electronic records of Henry Ford Hospital or internet support sites. Results: Aspirin use, having always been “Fit” and living alone were positively associated with AAID. Negative associations were observed for farming/pesticide exposure, years of education, being married, self description as a “Lone Wolf” or “Worrier”, taking “nerve” or “sleeping” pills, awakenings per night, Packyears of Smoking and the Interpersonal Sensitivity, Depression, Anxiety, Hostility and Paranoia scales of the Symptom Checklist 90 - Revised, as well as the AIAI (anger), Depression and Anxiety scales of the Spouse/Friend Ketterer Stress Symptom Frequency Checklist. Conclusions: Aspirin use and exercise may exert a modifiable delaying influence in the onset of CLL. Conversely, emotional distress and smoking may hasten its onset. Prospective, and interventional, tests of these findings are needed.
Cite this paper: M. Ketterer, E. Ketterer, B. Barthel, A. Hanbali, P. Kuriakose, Y. Guo and W. Knysz, "Correlates of Age at Initial Diagnosis of Chronic Lymphocytic Leukemia: Exercise, ASA & Emotional Distress," Open Journal of Medical Psychology, Vol. 1 No. 2, 2012, pp. 9-14. doi: 10.4236/ojmp.2012.12002.

[1]   American Cancer Society, “What Are the Risk Factors for Chronic Lymphocytic Leukemia?” 2007.

[2]   B. Holzner, G. Kemmler, M. Koop, D. Nguyen-Van-Tem, B. Sperner-Unterweger and R. Greil, “Quality of Life of Patients with Chronic Lymphocytic Leukemia Results of a Longitudinal Investigation over 1 Year,” European Journal of Haematology, Vol. 72, No. 6, 2004, pp. 381-389. doi:10.1111/j.1600-0609.2004.00233.x

[3]   T. D. Shanafelt, D. Bowen, C. Venkat, S. L. Slager, C. S. Zent, N. E. Kay, M. Reinalda, J. A. Sloan and T. G. Call, “Quality of Life in Chronic Lymphocytic Leukemia: An International Survey of 1482 Patients,” British Journal of Haematology, Vo. 139, No. 2, 2007, pp. 255-264. doi:10.1111/j.1365-2141.2007.06791.x

[4]   M. Else, A. G. Smith, K. Cocks, S. M. Richards, S. Crofts, R. Wade and D. Catovsky, “Patients’ Experience of Chronic Lymphocytia Leukemia: Baseline Health-Related Quality of Life Results from the Lrf CLL4 Trial,” British Journal of Haematology, Vol. 143, No. 5, 2008, pp. 690-697. doi:10.1111/j.1365-2141.2008.07407.x

[5]   B. F. Eichhorst, R. Busch, T. Obwundner, I. Kuhn-Hallek, P. Herschbach and M. Hallek, “Health-Related Quality of Life in Younger Patients with Chronic Lymphocytic Leukemia Treated with Fludarabine Plus Cyclophosphamide or Fludarabine Alone for First-Line Therapy: A Study by the German CLL Study Group,” Journal of Clinical Oncology, Vol. 25, No. 13, 2007, pp. 1722-1731. doi:10.1200/JCO.2006.05.6929

[6]   T. T. Levin, Y. Li, J. Riskind and K. Rai, “Depression, Anxiety and Quality of Life in a Chronic Lymphocytic Leukemia Cohort,” General Hospital Psychiatry, Vol. 29, No. 3, 2007, pp. 251-256. doi:10.1016/j.genhosppsych.2007.01.014

[7]   L. Cohen, G. D. Marshall, L. Cheng, S. K. Agarwal and Q. Wei, “DNA Repair Capacity in Healthy Medical Students during and after Exam Stress,” Journal of Behavioral Medicine, Vol. 23, No. 6, 2000, pp. 531-544. doi:10.1023/A:1005503502992

[8]   E. S. Epel, E. H. Blackburn, J. Lin, F. S. Dhabhar, N. E. Adler, J. D. Morrow and R. M. Cawthorn, “Accelerated Telomere Shortening in Response to Life Stress,” Proceedings of the National Academy of Sciences, Vol. 101, No. 49, 2004, pp. 17312-17315. doi:10.1073/pnas.0407162101

[9]   J. K. Kiecolt-Glaser, R. E. Stephens, P. D. Lipetz, C. E. Speicher and R. Glaser, “Distress and DNA Repair in Human Lymphocytes,” Journal of Behavioral Medicine, Vol. 8, No. 4, 1985, pp. 311-320. doi:10.1007/BF00848366

[10]   D. Ornish, J. Lin, J. Daubenmier, G. Weidner, E. Epel, C. Kemp, M. J. M. Magbanua, R. Marlin, L. Yglesias, L. Carroll and E. H. Blackburn, “Increased Telomerase Activity and Comprehensive Lifestyle Changes: A Pilot Study,” Lancet: Oncology, Vol. 10, No. 11, 2008, pp. 1048-1057.

[11]   R. Ader, “Psychoneuroimmunology,” 4th Edition, Academic Press, New York, 2006.

[12]   M. W. Ketterer, J. Brymer, K. Rhoads, P. Kraft, L. Kenyon, B. Foley, W. R. Lovallo and C. J. Voight, “Emotional Distress among Males with ‘Syndrome X’,” Journal of Behavioral Medicine, Vol. 19, No. 5, 1996, pp. 455-466. doi:10.1007/BF01857678

[13]   M. W. Ketterer, L. Kenyon, B. A. Foley, J. Brymer, K. Rhoads, P. Kraft P and W. R. Lovallo, “Denial of Depression as an Independent Correlate of Coronary Artery Disease,” Journal of Health Psychology, Vol. 1, No. 1, 1996, pp. 93-105. doi:10.1177/135910539600100108

[14]   M. W. Ketterer, J. Huffman, M. A. Lumley, S. Wassef, L. Gray, L. Kenyon, P. Kraft, J. Brymer, K. Rhoads, W. R. Lovallo and A. D. Goldberg, “Five-Year Follow-up for Adverse Outcomes in Males with at Least Minimally Positive Angiograms: Importance of ‘Denial’ in Assessing Psychosocial Risk Factors,” Journal of Psychosomatic Research, Vol. 44, No. 2, 1998, pp. 241-250. doi:10.1016/S0022-3999(97)00206-7

[15]   M. W. Ketterer, J. Denollet, J. Chapp, S. Keteyian, A. J. Farha, V. Clark, M. Hudson, A. Hakim, A. Greenbaum, J. Schairer and J. J. Cao, “Men Deny and Women Cry, but Who Dies? Do the Wages of ‘Denial’ Include Early Ischemic Coronary Heart Disease,” Journal of Psychosomatic Research, Vol. 56, No. 1, 2004, pp. 119-123. doi:10.1016/S0022-3999(03)00501-4

[16]   M. A. Lumley, J. L. Huffman, L. J. Rapport, S. K. Aurora, L. Norris and M. W. Ketterer, “Do Others Really Know Us Better? Predicting Migraine Activity from Self- and Other-Ratings of Negative Affect,” Journal of Psychosomatic Research, Vol. 58, No. 3, 2005, pp. 253-258. doi:10.1016/j.jpsychores.2004.09.005

[17]   R. C. Kneip, A. M. Delamater, T. Ismond, C. Milford, L. Salvia and D. Schwartz, “Self and Spouse Ratings of Anger and Hostility as Predictors of Coronary Heart Disease,” Health Psychology, Vol. 12, No. 4, 1993, pp. 301-302. doi:10.1037/0278-6133.12.4.301

[18]   A. W. Siegman, S. T. Townsend, R. S. Blumenthal, J. D. Sorkin and A. C. Civelek, “Dimensions of Anger and CHD in Men And Women: Self Ratings Versus Spouse Ratings,” Journal of Behavioral Medicine, Vol. 21, No. 4, 1998, pp. 315-336. doi:10.1023/A:1018725212562

[19]   T. W. Smith, B. N. Uchino, C. A. Berg, P. Florsheim, G. Pearce, M. Hawkins, P. N. Hopkins and H.-C. Yoon, “Hostile Personality Traits and Coronary Artery Calcification in Middle-Aged and Older Couples: Different Effects for Self-Reports versus Spouse Ratings,” Psychosomatic Medicine, Vol. 69, No. 5, 2007, pp. 441-448.

[20]   M. W. Ketterer, W. Knysz, M. Hudson, S. J. Keteyian and A. J. Farha, “Healthcare Utilization & Emotional Distress in Cad Patients,” Psychosomatics, Vol. 51, No. 4, 2010, pp. 297-301. doi:10.1176/appi.psy.51.4.297

[21]   American Sleep Disorders Association, “The International Classification of Sleep Disorders,” 1990.

[22]   L. D. Dugmore, R. J. Tipson, M. H. Phillips, “Changes in Cardiorespiratory Fitness, Psychological Wellbeing, Quality of Life and Vocational Status Following a 12 Month Cardiac Exercise Rehabilitation Programme,” Heart, Vol. 81, No. 4, 1999, pp. 359-366.

[23]   R. V. Milani, C. J. Lavie, M. M. Cassidy, “Effects of Cardiac Rehabilitation and Exercise Training Programs on Depression in Patients after Major Coronary events,” American Heart Journal, Vol. 132, No. 4, 1996, pp. 726-732. doi:10.1016/S0002-8703(96)90304-X

[24]   L. F. Cherkas, J. L. Hunkin, et al., “The Association between Physical Activity in Leisure Time and Leukocyte Telomere Length,” Archives of Internal Medicine, Vol. 168, No. 2, 2008, pp. 154-158. doi:10.1001/archinternmed.2007.39

[25]   M. W. Ketterer, J. Brymer, K. Rhoads, P. Kraft and W. R. Lovallo. “Is Aspirin, as Used for Anti-Thrombosis, an Emotion-Modulating Agent?” Journal of Psychosomatic Research, Vol. 40, No. 1, 1996, pp. 53-58. doi:10.1016/0022-3999(95)00524-2

[26]   K. S. Choe, P. R. Cowan, et al., “Aspirin Use and the Risk of Prostate Cancer Death in Men Treated with Prostatectomy or Radiotherapy: Results from the Capsure Database,” International Journal of Radiation Oncology, Biology, Physics, Vol. 78, No. 3, 2010, pp. 126-127.

[27]   C. M. Kasum, C. K. Blair, A. R. Folsom and J. A. Ross, “Non-Steroidal Anti-Inflammatory Drug Use and Risk of Adult Leukemia,” Cancer Epidemiology, Biomarkers & Prevention, Vol. 12., No. 6, 2003, pp. 534-537.

[28]   P. M. Rothwell, M. Wilson, C.-E. Elwin, B. Norving, A. Algra, C. P. Warlow and T. W. Meade, “Long-Term Effect of Aspirin on Colorectal Cancer Incidence and Mortality: 20-Year Follow-up of Five Randomized Trials,” The Lancet, Vol. 376, No. 9754, 2010, pp. 1741-1750. doi:10.1016/S0140-6736(10)61543-7

[29]   M. Pigrone, C. Phillips and C. Mulrow, “Use of Lipid-Lowering Drugs for Primary Prevention of Coronary Heart Disease: Meta-Analysis of Randomized Trials,” British Medical Journal, Vol. 321, 2000, pp. 983-989. doi:10.1136/bmj.321.7267.983

[30]   J. Sheperd, G. J. Blauw, et al., “Pravastatin in Elderly Individuals at Risk of Vascular Disease (PROSPER): A Randomized Controlled Trial,” The Lancet, Vol. 360, No. 9346, 2002, pp. 1623-1630. doi:10.1016/S0140-6736(02)11600-X

[31]   O. Nanni, D. Amadori, C. Lugaresi, F. Falcini, E. Scarpi E. A. Saragoni and E. Buiatti, “Chronic Lymphocytic Leukaemias and Non-Hogkin’s Lymphomas by Histological Type in Farming-Animal Breeding Workers: A Population Case-Control Study Based on a Priori Exposure Matrices,” Occupational & Environmental Medicine, Vol. 53, No. 10, 1996, pp. 652-657. doi:10.1136/oem.53.10.652

[32]   T. Zheng A. Blair, Y. Zhang, D. D. Weisenberger and S. H. Zahm, “Occupation and Risk of Non-Hodgkin’s Lymphoma and Lymphocytic Leukemia,” Journal of Occupa-tional & Environmental Medicine, Vol. 44, No. 5, 2002, pp. 469-474. doi:10.1097/00043764-200205000-00015

[33]   L. R. Derogatis, “Symptom Checklist 90 - Revised,” NCS Assessments, Minneapolis, 1977.

[34]   M. W. Ketterer, “Denial Specific to Friedman’s Pathogenic Emotions in Jenkins Activity Survey Type A and Angiography-Referred Males,” Psychosomatics, Vol. 33, No. 1, 1992, pp. 72-80.

[35]   M. W. Ketterer, W. R. Lovallo and M. A. Lumley, “Quantifying the Density of Friedman’s Pathogenic Emotions (Aiai),” International Journal of Psychosomatics, Vol. 40, No. 1-4, 1993, pp. 22-28.

[36]   D. Waterhouse, W. J. Carmen, D. Shottenfeld, G. Gidley and S. McLean, “Cancer Incidence in the Rural Community of Tecumseh, Michigan: A Pattern of Increased Lymphopoietic Neoplasms,” Cancer, Vol., 77, No. 4, 1996, pp. 763-770. doi:10.1002/cncr.1996.2820770402

[37]   M. W. Ketterer, G. Mahr and A. D. Goldberg, “Psychological Factors Affecting a Medical Condition,” Journal of Psychosomatic Research, Vol. 48, No. 4-5, 2000, pp. 357-368. doi:10.1016/S0022-3999(00)00099-4